
ongoing trials - trial from www.clinicaltrials.gov

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes - Phase 2|Phase 3 - Not yet recruiting

Code: NCT06149793 **Year:** 2023 **Date:** December 30, 2023

Author: Amir Moheet|University of Minnesota

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment

Participants

Cystic Fibrosis-related Diabetes|Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

Interventions

Drug: Empagliflozin|Other: Placebo Control

Outcome measures

Feasibility, safety, tolerability

<https://ClinicalTrials.gov/show/NCT06149793>

Keywords

Empagliflozin; SGLT2 inhibitors; Hypoglycemic Agents; pharmacological_intervention;